LanguaTalk

BioCentury This Week

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

Ep. 259 - Causal Biology and Big Data, Ultra-Rare Drugs at FDA

33 mins; October 14, 2024

Ep. 258 - Breaking the Bear: 4Q Public Markets Preview

39 mins; October 07, 2024

Ep. 257 - Schizophrenia, Sickle Cell Drugs, D.C. Update

32 mins; September 30, 2024

Ep. 256 - ESMO Recap: Keeping TIGIT Alive, Rybrevant & Immunotherapy Anniversary

26 mins; September 25, 2024

Ep. 255 - Pediatric PRVs, Biosecure & Novo's Obesity Miss

21 mins; September 23, 2024

Ep. 254 - Takeaways from Grand Rounds 2024

34 mins; September 20, 2024

Ep. 253 - IPOs, GLP-1 & Obesity, AI & Biotech

32 mins; September 16, 2024

Ep. 252 - Akeso's Bispecific, Vaxcyte & Woodcock's Quality Mindset

18 mins; September 09, 2024

Ep. 251 - Eyes on the target: a Back to School Overview

31 mins; September 06, 2024

Ep. 250 - Biosecure, Priority Review Vouchers & Target Discovery

30 mins; September 04, 2024

Ep. 249 - Biotech IPO Buzz, Pharma Deal Trends, Washington Update

29 mins; August 26, 2024

Ep. 248 - Grand Rounds Preview: Eyes on the Target

33 mins; August 22, 2024

Ep. 247 - Drug Pricing, Psychedelic Setback & Back to School

25 mins; August 19, 2024

Ep. 246 - Wilson’s Vision for Gene Therapy. Plus: Korea Biotech & Grand Rounds

32 mins; August 12, 2024

Ep. 245 - Biotech-Academia Deals, Leqembi's Latest, Wilson Moves On

25 mins; August 05, 2024

Ep. 244 - Leqembi's Thumbs-Down in Europe. Plus: Perioperative Cancer, Pediatric Review Vouchers

29 mins; July 29, 2024

Ep. 243 - Radiopharma Alpha Emitters, AZ’s Galbraith and LNPs

29 mins; July 22, 2024

Ep. 242 - 3Q Markets Preview, Washington Update, Lisa Burns

25 mins; July 15, 2024

Ep. 241 - U.K. Biopharma on the Move. Plus: IRA, Biosecure

18 mins; July 08, 2024

Ep. 240 - Chevron Ruling's Impact. Plus: Tumor Targets, Lurie Winner

21 mins; July 01, 2024

Ep. 239 - Rare Disease Spotlight: MPS & DMD

24 mins; June 24, 2024

Ep. 238 - Biosecure Act: The Impact & What's Ahead

22 mins; June 20, 2024

Ep. 237- Pandemic Prep Problems, Reverse Mergers, Alzheimer’s & SCOTUS

28 mins; June 17, 2024

Ep. 236 - BIO Wrap: Biosecure, Japan & Nxera, Radiopharma

26 mins; June 13, 2024

Ep. 235 - Psychedelic Setback, FDA's Platform Play & ASCO Innovations

29 mins; June 10, 2024

Ep. 234 - Biotech M&A, Biosecure Expands & ASCO Update

28 mins; June 03, 2024

Ep. 233 - ASCO Preview, Rare Diseases & Biogen M&A

26 mins; May 28, 2024

Ep. 232 - Shake up at BIO. Plus: ASGCT highlights, new IPF & obesity data

26 mins; May 20, 2024

Bonus Content - Derek Lowe Unplugged: AI; Biosecure; FDA, Abortion & SCOTUS; and more

32 mins; May 16, 2024

Ep. 231 - Biosecure Revised. Plus: Venture Rounds, Deals of Note

25 mins; May 13, 2024

Bonus Content - Ysios' Karen Wagner: How Europe's Biotechs Can Rise Above the Noise

31 mins; May 09, 2024

Ep. 230 - Bio€quity Europe 2024 Preview

25 mins; May 08, 2024

Ep. 229 - ASGCT Preview, Accelerated Approval Plus: The Latest in Biosecure

28 mins; May 06, 2024

Ep. 228 - Energizing Gene Therapy. Plus: AI Newco, Ono-Deciphera

23 mins; April 29, 2024

Ep. 227 - Defending Accelerated Approval. Plus: Endpoint Innovation & AIM Amiss

22 mins; April 22, 2024

Ep. 226 - Vertex’s Alpine Buy, Goldman’s Venture & IRA Tea Leaves

22 mins; April 15, 2024

Ep. 225 - 2Q Markets Preview & AACR Takeaways

21 mins; April 08, 2024

Ep. 224 - Biotech IPOs, Avalon & FDA at SCOTUS

21 mins; April 01, 2024

Ep. 223 - Biosecure, Bruce Booth & Ultrarare Drugs

28 mins; March 25, 2024

Ep. 222 - Crowley’s Vision for BIO, Plus: MASH & CAR Ts

20 mins; March 18, 2024

Ep. 221 - China Biocontroversy, Plus: Diversity Matters

31 mins; March 11, 2024

Ep. 220 - Biotech’s Financing Flurry & Distillery Spotlight

24 mins; March 04, 2024

Ep. 219 - East-West Summit Preview

25 mins; February 27, 2024

Ep. 218 - Bob Nelsen Insights, TL1A, Rare Diseases

24 mins; February 26, 2024

Ep. 217 - Safer CAR Ts & World’s First TIL Therapy

24 mins; February 20, 2024

Ep. 216 - Anti-China Biotech Policy: Biosecure & Beyond

26 mins; February 15, 2024

Ep. 215 - ADCs, Psychedelics & IPOs

24 mins; February 12, 2024

Ep. 214 - BMS’s Patent Cliff, Congress Targets China Biotech

29 mins; February 05, 2024

Ep. 213 - Biotech IPOs & IL-18 Momentum

28 mins; January 29, 2024

Ep. 212 - 2024 Buyside View & Arnold Ventures' Impact

30 mins; January 22, 2024

Ep. 211 - 2024 Markets Preview, Woodcock's Legacy

22 mins; January 16, 2024

Ep. 210 - J.P. Morgan Healthcare Conference Wrap

27 mins; January 12, 2024

Ep. 209 - Biotech M&A, Innovation, Public Policy in 2024

37 mins; January 04, 2024

Ep. 208 - XBI Rally, ASH Highlights & '24 Picks

24 mins; December 18, 2023

Ep. 207 - Sickle Cell, AbbVie Deals, BIO CEO, March-in

30 mins; December 11, 2023

Ep. 206 - Roche, AbbVie Deals; Plus: FDA & CAR T

19 mins; December 04, 2023

Ep. 205 - Radiotherapy Deep Dive; Plus: Congress, BioNTech

25 mins; November 27, 2023

Ep. 204 - First CRISPR Approval & IRA’s Lost Orphans

29 mins; November 20, 2023

Ep. 203 - POC for Verve? Plus: IRA & East-West Deals

21 mins; November 13, 2023

Ep. 202 - A DMD Decision & Endpoint Innovation

30 mins; November 06, 2023

Ep. 201 - ESMO, NIH & IRA

17 mins; October 30, 2023

Ep. 200 - Merck-Daiichi, Roche-Roivant, Base Editors

27 mins; October 23, 2023

Ep. 199 - China Summit Preview

23 mins; October 20, 2023

Ep. 198 - Novartis Finds Focus & EU Pharma Law

27 mins; October 16, 2023

Ep. 197 - Mirati Takeout & 4Q23 Financial Markets Preview

28 mins; October 09, 2023

Ep. 196 - CAR T's Next Act & Hudson's Vision for Sanofi

29 mins; October 02, 2023

Ep. 195 - East-West Summit Preview

19 mins; September 25, 2023

Ep. 194 - IPO Outlook & IRA Lawsuits

24 mins; September 18, 2023

Ep. 193 - East-West CAR T Deals, Plus: Amgen-FTC

22 mins; September 11, 2023

Ep. 192 - Tier-jumpers: a Back to School Overview

32 mins; September 05, 2023

Ep. 191 - Circular RNA, Psychedelics, & Upcoming BioCentury Summits

22 mins; August 21, 2023

Ep. 190 - Obesity Mechanisms, Noubar Takeaways, Scleroderma Platform Trial

18 mins; August 14, 2023

Ep. 189 - Biogen-Sage Setback, Biotech IPOs, Sanofi Digital

22 mins; August 07, 2023

Ep. 188 – Pharma deals; Plus: Genentech, Leerink Conversations

25 mins; July 31, 2023

Ep. 187 - Alnylam-Roche; Plus: Insights on the IRA, FTC

24 mins; July 24, 2023

Ep. 186 - 3Q Markets Preview, Donanemab & Lilly-Versanis

19 mins; July 17, 2023

Ep. 185 - Leqembi's Launch, Biotech IPOs, Sarepta Approval

25 mins; July 10, 2023

Ep. 184 - Califf's FDA reforms & Polaris' Schulman

27 mins; June 26, 2023

Ep. 183 - EMA's Cooke, What's Next for IPSCs, & Leerink is Back

30 mins; June 19, 2023

Ep. 182 - Merck’s IRA suit, Leqembi and MCEDs at ASCO

30 mins; June 12, 2023

Ep. 181 - Highlights from ASCO

25 mins; June 05, 2023

Ep. 180 - ASCO, Neuropsych & the IRA

19 mins; May 30, 2023

Ep. 179 - DMD Gene Therapies, CBER & NIH

27 mins; May 22, 2023

Ep. 178 - Live from Bio€quity, Part 2

19 mins; May 16, 2023

Ep. 177 - Live from Bio€quity, Part 1

22 mins; May 15, 2023

Ep. 176 - Bio€quity Europe 2023 Preview: Crafting a European Playbook for Success

23 mins; May 09, 2023

Ep. 175 - Acelyrin IPO, Alzheimer's Data & Digital Endpoints

25 mins; May 08, 2023

Ep. 174 - EC Pharma Law, ALS Biomarker, Astellas' Iveric Deal

24 mins; May 01, 2023

Ep. 173 - EU VC Funds, Abortion Drug Ruling, IRA Insights

23 mins; April 24, 2023

Ep. 172 - AACR Insights

22 mins; April 20, 2023

Ep. 171 - 2Q Markets Preview, Abortion Drug Rulings, Gilead Oncology

28 mins; April 17, 2023

Ep. 170 - Abortion Ruling & FDA; New VC Funds; IRA

19 mins; April 10, 2023

Ep. 169 - FTC & Illumina, Plus: PCSK9s at SCOTUS

22 mins; April 03, 2023

Ep. 168 - VCs' Take on SVB & New ALS Endpoint

21 mins; March 27, 2023

Ep. 167 - The IRA, T Cell Therapies & The Distillery

22 mins; March 20, 2023

Ep. 166 - SVB Shakeout: Next Steps for Biotech

23 mins; March 17, 2023

Ep. 165 - SVB Fallout, Plus: Pfizer-Seagen

24 mins; March 13, 2023

Ep. 164 - Viehbacher’s Vision, NK Cells & Bat Biotech

26 mins; March 06, 2023

Ep. 163 - EU Pharma Law Overhaul, Abortion Drug Ruling, Dunn's Departure

24 mins; February 27, 2023

Ep. 162 - New CMS Payment Models, China Markets Outlook, & Zhang's Latest Start-Up

21 mins; February 21, 2023

Click here to see more

BioCentury This Week

Useful pages

Find a tutor

Languages